Skip to main content

Atrial Fibrillation Screening-to-Anticoagulation Pathways in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis

In brief

Only 23% of eligible high-risk patients received anticoagulants in LMIC studies

Across 37 reports from 13 low- and middle-income countries, anticoagulant coverage averaged 22.8% among participants considered eligible or high risk; confirmed atrial fibrillation averaged 1.24% in community screening studies. These estimates came from different study subsets, varied widely, and are not predictions for any one setting, underscoring the need to link screening with diagnosis, treatment access, and follow-up.

Journal
JACC. Advances (Q1)
Published
16 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Eyad Jamileh, Fahad Muhammad, Omar Farooq, Sadeer Al-Kindi, Zainab Dakhil, Mirvat Alasnag, et al.
PMID
43038801
DOI
10.1016/j.jacadv.2026.103479

Why clinicians should know about it

  • Picked for Epidemiology (top studies of the week, 22 November 2026): Screening pathway review examines reach, equity, confirmation, and treatment

Abstract

BACKGROUND: Atrial fibrillation (AF) is an important cause of preventable stroke in low- and middle-income countries (LMICs), where diagnostic and treatment gaps may limit screening effectiveness. OBJECTIVES: This study aims to evaluate AF screening in LMICs as a screening-to-anticoagulation pathway, focusing on reach, equity, diagnostic confirmation, anticoagulation uptake, and health-system capacity. METHODS: MEDLINE via PubMed, Embase, CINAHL, Web of Science, and CENTRAL were searched from inception to July 2026. LMIC studies reporting population-facing AF screening or screening-linked care were included. Logit-transformed proportions were pooled using restricted maximum-likelihood random-effects models with modified Hartung-Knapp CIs; binomial-normal generalized linear mixed models were used in sensitivity analyses. Pathway stages were synthesized from outcome-specific study subsets rather than a single longitudinal cohort. RESULTS: Thirty-seven reports from 13 LMICs and 1 multinational cohort were included. Across 22 community- or population-based studies, confirmed AF averaged 1.24% (95% CI: 0.79%-1.94%; I2 = 98.8%; 95% prediction interval: 0.16%-8.83%). Newly detected AF averaged 0.95% (95% CI: 0.43%-2.11%; I2 = 99.2%; prediction interval: 0.08%-9.97%). In separate study subsets, prior AF awareness was 50.7%, study-defined high stroke risk or oral anticoagulation indication was 78.9%, and oral anticoagulation coverage among study-defined eligible/high-risk participants was 22.8%. Reach ranged from 9.7% to 98.8%, and confirmation completion was 57.5% to 61.8% in 2 programs. CONCLUSIONS: AF screening in LMICs identifies substantial but highly variable detection and treatment gaps. Pooled proportions should be interpreted as cross-study summaries rather than expected rates for a specific setting. Effective programs require representative reach, timely confirmation, appropriate stroke-risk and valvular assessment, access to anticoagulation, and longitudinal follow-up.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.